Phase I results support daily subcutaneous dosing of Apellis Pharmaceuticals' APL-2 June 27, 2016 No Comments
Hillhurst Biopharmaceuticals receives grant for HBI-002 in sickle cell disease May 25, 2016 No Comments
RSS